Innovation and R&D

International consortia projects to transform drug development

Innovation is not only part of InnoSer’s name but is also central to its activities. We are proud to be taking part in several research and development projects that unite in vitro and in vivo methods. We collaborate with a variety of academic and commercial partners to ultimately bring innovation to the preclinical drug development space. These international consortia projects are funded by prestigious bodies such as: Eurostars, a joint initiative of EUREKA and the European Union; and VLAIO, the Flemish governmental organization for innovation and entrepreneurship.

Our collaborations not only result in new platforms for reliable and efficient drug development, but also puts us at the forefront of scientific developments and knowledge. This way we both contribute to the wider knowledge of the scientific community, and apply the best in constructing the studies we offer as a service.

Our Innovative Projects

Consortia projects
innovation pdxo

PDXO – VLAIO

Goal

To develop an integrated drug screening platform consisting of highly translatable in vitro, patient-derived organoid (PDO), and in vivo, patient-derived xenograft (PDX), models.

InnoSer’s role

In collaboration with its partners InnoSer develops both PDX and PDO models in-house using primary patient tissues that are acquired by partner medical institutions. Then, InnoSer contributes to the project by characterizing and storing these models in a biobank for commercial use.

Read further >>

innovation lemonaid

Lemonaid – Eurostars (E!113873/22), VLAIO

Goal

To develop a novel therapeutic compound targeted at Diffuse Large-Cell B-cell Lymphoma (DLBCL) using a new class of drugs.

InnoSer’s role

InnoSer develops a patient-derived DBCL organoid platform for drug testing, validates this platform and compares it to a transgenic DLBCL in vivo model developed by its partner. InnoSer also performs in-house drug efficacy screening of the lead-compounds developed using said models.

Read further >>

innovation mindmap

MINDMAP – Eurostars (E!19206), RVO

Goal

Development of a novel 3D BoC model for Alzheimer’s disease drug development. Combining 3D cultures of IPS derived neurons, integrated in a microfluidic chip, with an artificial intelligence platform to allow for assessment of neuronal network activity at single-cell level.

InnoSer’s role

InnoSer contributes to the optimization of the MINDMAP platform for the intended use in a preclinical screening setting. InnoSer ensures stabile translation and integration of the individual technologies by validating its effectiveness in distinguishing healthy versus diseased conditions as well as the effects of AD research compounds.

Read further >>

innovation transcend

TRANSCEND – Eurostars (E!114817), VLAIO

Goal

Development of an integrated drug development platform consisting of novel in vitro (organoid) and humanized in vivo models for Parkinson’s disease. Distinguishing features of this platform are the integration of microglial cells and humanized dopaminergic precursors.

InnoSer’s role

Development of the new humanized in vivo model for Parkinson’s disease. InnoSer is responsible for the integration of human dopaminergic precursors and microglia in immuno-compromised mice. InnoSer validates the model in-house and uses it to assess standards-of-care therapeutics for PD.

Read further >>

innovation nanoplus

Nano+ – Health~Holland, TKI / LSH

Goal

Fundamental research in the development of a novel brain-on-chip model for neurodegenerative diseases based on the application of 3D nanogroove-aligned human induced pluripotent stem cell-derived neurons and electrophysiological measurements.

InnoSer’s role

InnoSer contributes knowledge and expertise on the translation of novel technologies into plug-and-play services for preclinical drug development.

Read further >>

innovation connect

CONNECT – NWO

Goal

Development of an in vitro model connecting iPSC-derived Blood-Brain Barrier blood vessels to cerebral organoids. This platform will function as a predictive tool for the delivery (and efficacy) of potential compounds into the brain.

InnoSer’s role

InnoSer will contribute its knowledge and expertise to shape this truly unique platform into a commercially attractive solution for drug screening, working towards the acceleration of preclinical research in the field of neurodegenerative diseases.

Read further >>

innovation cystarrest

CystArrest – Eurostars (E!12512), VLAIO

Goal

Development of a novel therapeutic drug for the treatment of Polycystic Kidney Disease

InnoSer’s role

The LUMC develops and characterizes a new ADPKD conditional mouse model (Pkd1 -/- cKo) which is then transferred to InnoSer’s facilities. InnoSer then demonstrates in vivo efficacy of a selected compound by using the model.

Read further >>

innovation heartchip

HeartCHIP II – Health~Holland, TKI/LSH

Goal

The HeartCHIP II project develops a novel automated high-throughput (HT) drug screening system to identify promising candidates for HF. The system uniquely uses functional video microscopy of heart tissue cultures as a read-out parameter which is combined with OoC technology and HF disease models.

InnoSer’s role

InnoSer performs a benchmark study of HeartCHIP II’s 3D multi-cell cultures against standardized and validated animal models for HF such as MYCBP3 mutant mice, testing functional outcome after treatment with inotropic compounds.

Ready to Innovate with InnoSer?

Get in touch with us.